FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220908341> ?p ?o ?g. }

• W4220908341 endingPage "17" @default.
• W4220908341 startingPage "P2" @default.
• W4220908341 abstract "Abstract Amplification and/or overexpression of HER2 in breast cancer (BCa) patients is associated with aggressive disease and poor prognosis. Herceptin® (trastuzumab), a monoclonal antibody targeting HER2, has an established role in the treatment of HER2 positive BCa. Addition of trastuzumab to anthracycline- and taxane-based neoadjuvant treatment in women with HER2-positive BCa has resulted in improvements in pathological complete response (pCR, a strong predictor for long-term clinical outcome), event-free survival (EFS) and overall survival (OS). This study is designed to compare efficacy (pCR) and safety between the originator Herceptin and the proposed trastuzumab biosimilar EG12014. The study is conducted during the COVID-19 pandemic (last patient in: March 2020, last patient last visit: planned Jan 2022) in Belarus, Chile, Colombia, Georgia, India, Russia, South Africa, South Korea, Taiwan, and the Ukraine. Methods: Neoadjuvant phase: 807 patients were randomized (1:1) into 2 arms receiving epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks for 4 cycles, followed by EG12014 (arm 1) or Herceptin (arm 2) (both at loading dose: 8 mg/kg and maintenance dose: 6 mg/kg) and paclitaxel (175 mg/m2) every 3 weeks for 4 cycles. Subsequently, the patients underwent surgery, and primary endpoint (pCR [ypT0/is ypN0]) was assessed. Adjuvant phase: After surgery, the patients received EG12014 or Herceptin (both at loading dose: 8 mg/kg and maintenance dose: 6 mg/kg) to complete 12 months of overall trastuzumab treatment. COVID-19 infections in the study population were not expected to affect primary endpoint analysis; thus, no sensitivity analysis was performed regarding COVID-19 status (symptomatic/asymptomatic). Differences between the 2 arms regarding delays in study treatments and procedures due to COVID-19 were assessed. Results (at interim data base lock, blinded as study is ongoing): Study population: the mean age was 50 years, the majority were white Europeans with tumor stage II, estrogen receptor positive and progesterone receptor negative. The median time from date of first diagnosis was 0.5 months. Primary endpoint pCR (ypT0/is ypN0) was reached with relative risk ratio (RR) for the full analysis set: 0.992 (90% CI 0.880 to 1.118) between the 2 treatment arms. Secondary pCR endpoints (defined as ypT0 ypN0 and ypT0/is) were also reached, with RR between the treatment arms: 0.917 and 0.992, respectively. Objective clinical response prior to surgery was similar for the 2 treatment arms: 83.8% and 83.6%, respectively. EFS, OS, safety endpoints (e.g., adverse events [most frequently reported: alopecia], serious adverse events, and deaths), and toxicity assessments, supported similarity between EG12014 and Herceptin. Sixty-two patients (7.7%) were infected with COVID-19; the infections were equally distributed between the 2 treatment arms. COVID-19 did not cause any discontinuations or deaths in the study. Among all reported COVID-19 events, 13 (21%) were asymptomatic, 11 (18%) were graded as 3 (severe), and 1 (1.6%) was graded as grade 4 (life threatening). Conclusion: EG12014 has shown equivalent efficacy to Herceptin in regard to clinical response (pCR) and has also demonstrated a similar safety profile. The impact of the COVID-19 pandemic has been comparable between the two treatment arms. The influence of the pandemic on this clinical study has been relatively low considering timing and the participating countries. For further information, visit ClinicalTrials.gov (NCT03433313). Citation Format: Barbara Grohmann-Izay, Chiun-Sheng Huang, Giorgi Dzagnidze, Nestor Llinas, Anand Misra, Denys Pominchuk, Alexander Prokhorov, Bernardo Rapoport, Vladimir Semiglazov, Ling-Ming Tseng, Eduardo Yanez Ruiz, Sibylle Loibl. A phase III, randomized, multicenter, double-blind study to compare efficacy and safety of EG12014 (EirGenix trastuzumab) with Herceptin® as neoadjuvant treatment in combination with anthracycline/paclitaxel-based systemic therapy in patients with HER2-positive early breast cancer - a multinational phase III study conducted during the COVID-19 pandemic [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-13-17." @default.
• W4220908341 created "2022-04-03" @default.
• W4220908341 creator A5002463805 @default.
• W4220908341 creator A5031485783 @default.
• W4220908341 creator A5032340945 @default.
• W4220908341 creator A5037542905 @default.
• W4220908341 creator A5039383124 @default.
• W4220908341 creator A5043177871 @default.
• W4220908341 creator A5055292882 @default.
• W4220908341 creator A5058246510 @default.
• W4220908341 creator A5068100907 @default.
• W4220908341 creator A5076028497 @default.
• W4220908341 creator A5088710480 @default.
• W4220908341 creator A5091353701 @default.
• W4220908341 date "2022-02-15" @default.
• W4220908341 modified "2023-10-11" @default.
• W4220908341 title "Abstract P2-13-17: A phase III, randomized, multicenter, double-blind study to compare efficacy and safety of EG12014 (EirGenix trastuzumab) with Herceptin® as neoadjuvant treatment in combination with anthracycline/paclitaxel-based systemic therapy in patients with HER2-positive early breast cancer - a multinational phase III study conducted during the COVID-19 pandemic" @default.
• W4220908341 doi "https://doi.org/10.1158/1538-7445.sabcs21-p2-13-17" @default.
• W4220908341 hasPublicationYear "2022" @default.
• W4220908341 type Work @default.
• W4220908341 citedByCount "1" @default.
• W4220908341 countsByYear W42209083412022 @default.
• W4220908341 crossrefType "journal-article" @default.
• W4220908341 hasAuthorship W4220908341A5002463805 @default.
• W4220908341 hasAuthorship W4220908341A5031485783 @default.
• W4220908341 hasAuthorship W4220908341A5032340945 @default.
• W4220908341 hasAuthorship W4220908341A5037542905 @default.
• W4220908341 hasAuthorship W4220908341A5039383124 @default.
• W4220908341 hasAuthorship W4220908341A5043177871 @default.
• W4220908341 hasAuthorship W4220908341A5055292882 @default.
• W4220908341 hasAuthorship W4220908341A5058246510 @default.
• W4220908341 hasAuthorship W4220908341A5068100907 @default.
• W4220908341 hasAuthorship W4220908341A5076028497 @default.
• W4220908341 hasAuthorship W4220908341A5088710480 @default.
• W4220908341 hasAuthorship W4220908341A5091353701 @default.
• W4220908341 hasConcept C121608353 @default.
• W4220908341 hasConcept C126322002 @default.
• W4220908341 hasConcept C141071460 @default.
• W4220908341 hasConcept C143998085 @default.
• W4220908341 hasConcept C203092338 @default.
• W4220908341 hasConcept C2776802502 @default.
• W4220908341 hasConcept C2777511904 @default.
• W4220908341 hasConcept C2778292576 @default.
• W4220908341 hasConcept C2779786085 @default.
• W4220908341 hasConcept C2780835546 @default.
• W4220908341 hasConcept C2908647359 @default.
• W4220908341 hasConcept C530470458 @default.
• W4220908341 hasConcept C535046627 @default.
• W4220908341 hasConcept C71924100 @default.
• W4220908341 hasConcept C99454951 @default.
• W4220908341 hasConceptScore W4220908341C121608353 @default.
• W4220908341 hasConceptScore W4220908341C126322002 @default.
• W4220908341 hasConceptScore W4220908341C141071460 @default.
• W4220908341 hasConceptScore W4220908341C143998085 @default.
• W4220908341 hasConceptScore W4220908341C203092338 @default.
• W4220908341 hasConceptScore W4220908341C2776802502 @default.
• W4220908341 hasConceptScore W4220908341C2777511904 @default.
• W4220908341 hasConceptScore W4220908341C2778292576 @default.
• W4220908341 hasConceptScore W4220908341C2779786085 @default.
• W4220908341 hasConceptScore W4220908341C2780835546 @default.
• W4220908341 hasConceptScore W4220908341C2908647359 @default.
• W4220908341 hasConceptScore W4220908341C530470458 @default.
• W4220908341 hasConceptScore W4220908341C535046627 @default.
• W4220908341 hasConceptScore W4220908341C71924100 @default.
• W4220908341 hasConceptScore W4220908341C99454951 @default.
• W4220908341 hasIssue "4_Supplement" @default.
• W4220908341 hasLocation W42209083411 @default.
• W4220908341 hasOpenAccess W4220908341 @default.
• W4220908341 hasPrimaryLocation W42209083411 @default.
• W4220908341 hasRelatedWork W2012920290 @default.
• W4220908341 hasRelatedWork W2084016080 @default.
• W4220908341 hasRelatedWork W2142058321 @default.
• W4220908341 hasRelatedWork W2163622510 @default.
• W4220908341 hasRelatedWork W2219651576 @default.
• W4220908341 hasRelatedWork W2225859329 @default.
• W4220908341 hasRelatedWork W2362550559 @default.
• W4220908341 hasRelatedWork W2419163467 @default.
• W4220908341 hasRelatedWork W3151758858 @default.
• W4220908341 hasRelatedWork W4298395588 @default.
• W4220908341 hasVolume "82" @default.
• W4220908341 isParatext "false" @default.
• W4220908341 isRetracted "false" @default.
• W4220908341 workType "article" @default.